Andere talen Sequana Medical N.V.

Aandelen

SEQUA

BE0974340722

Beurs gesloten - Euronext Bruxelles Andere beurzen 17:39:15 18-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
1,475 ^EUR	+3,51%		-1,67%	-63,12%

11/04	Brusselse beurs opent aarzelend	AM
07/04	Brusselse beurs begint nieuw kwartaal terughoudend	AM

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Sequana Medical Announces Strong Data from DSR Proof-of-Concept Studies in Heart Failure Published in European Journal of Heart Failure	03/04
Sequana Medical NV Reports Earnings Results for the Full Year Ended December 31, 2023	28/03
Sequana Medical NV Announces Three Month Follow-Up Data from MOJAVE Non- Randomized Cohort Confirming Significant Improvement in Diuretic Response and Virtual Elimination of Loop Diuretics Following DSR Therapy	25/03
Sequana Medical Raises EUR11.5 Million via Share Placement	21/03
Sequana Medical's Premarket Application for Alfapump Accepted by US FDA; Shares Rise	29/01
Sequana Medical Receives New US Reimbursement Codes for Alfapump System	03/01
Sequana Medical submits Premarket Approval application to US FDA for alfapump in recurrent or refractory ascites due to liver cirrhosis	29/12
Belgium's Sequana Medical Seeks US FDA Premarket Approval for Liver Ascites Treatment Device	28/12
Sequana Medical N : announces positive data from non-randomized cohort in US Phase 1/2a MOJAVE study of DSR® 2.0 for treatment of heart failure	29/11
Sequana Medical NV Announces Positive Data from Non- Randomized Cohort in US Phase 1/2a MOJAVE Study of DSR® 2.0 for Treatment of Heart Failure	29/11
Sequana Medical NV Appoints Ids Van Der Weij as Non-Executive Director	10/11
Certain Shares of Sequana Medical NV are subject to a Lock-Up Agreement Ending on 22-OCT-2023.	22-10-23
Sequana Medical N : announces additional alfapump data supporting strong and durable clinical profile; PMA on track for year-end submission	19-10-23
Sequana Medical N : announces initial positive data from MOJAVE, a US Phase 1/2a study of DSR® 2.0 for treatment of heart failure through breaking vicious cycle of cardiorenal syndrome	18-10-23
Sequana Medical NV Announces Initial Positive Data from MOJAVE, a US Phase 1/2A Study of DSR 2.0 for Treatment of Heart Failure through Breaking Vicious Cycle of Cardiorenal Syndrome	18-10-23
Sequana Medical N : announces Extraordinary General Meeting of Shareholders on 10 November 2023	06-10-23
Sequana Medical N : Special report of the Board of Directors	05-10-23
Sequana Medical N : ANNOUNCES NEW SHARE CAPITAL AMOUNT AND NEW NUMBER OF SHARES	05-10-23
Sequana Medical NV Reports Earnings Results for the Half Year Ended June 30, 2023	14-09-23
Sequana Medical N : announces H1 2023 results and provides business update	14-09-23

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Sequana Medical N.V.

Aandelen

SEQUA

BE0974340722

Andere talen

Filters